Understanding how cocaine addiction affects gene expression during abstinence
Epigenetic mechanisms of sustained transcription across cocaine abstinence
This study is looking at how certain genes in the brain can stay active even after someone stops using cocaine, which might help explain why some people struggle to stay off the drug; by focusing on a specific protein called Nr4a1, the researchers hope to find new ways to support recovery and prevent relapse.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11091565 on NIH RePORTER |
What this research studies
This research investigates the molecular mechanisms that allow certain gene expressions to persist in the brain even after a person has stopped using cocaine. By focusing on a specific transcription factor called Nr4a1, the study aims to uncover how changes in gene expression contribute to the risk of relapse in individuals recovering from cocaine addiction. The researchers will utilize advanced techniques, including CRISPR technology, to analyze how these genetic changes occur and persist over time. This work could lead to new therapeutic strategies to help individuals maintain abstinence from cocaine.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have a history of cocaine use and are currently in a state of abstinence.
Not a fit: Patients who have never used cocaine or those who are actively using cocaine may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that help prevent relapse in individuals recovering from cocaine addiction.
How similar studies have performed: Other research has shown promise in understanding the genetic factors involved in addiction, but this specific approach using CRISPR technology is relatively novel.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Heller, Elizabeth a — University of Pennsylvania
- Study coordinator: Heller, Elizabeth a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.